๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Extensive-Stage Small Cell Lung Cancer
Clinical trial register · China

Extensive-Stage Small Cell Lung Cancer Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Shanghai 9 Beijing 7 Chongqing 5 Guangzhou 4 Zhengzhou 4
Narrow the registerReset
Recruitment status
Phase
Site location
Shanghai9 Beijing7 Chongqing5 Guangzhou4 Zhengzhou4
All 35 locations
Target enrolment
to

Extensive-Stage Small Cell Lung Cancer trials in China

21 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
A Study of BL-M14D1 in Combination With Atezolizumab in Patients With Extensive-stage Small Cell Lung Cancer
NCT07654400Extensive-stage Small-cell Lung Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
36
Shanghai
2026-07-09
Active, closed
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
NCT07005128Small-cell Lung Cancer, Extensive Stage Small-cell Lung Cancer
Amgen
Phase 3
350
Beijing, Quanzhou, Harbin, Jiamusi, Zhengzhou, Nanchang, Jinan, Shanghai
2025-08-18
Recruiting
Sintilimab Combined With Tafolecimab and Chemotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer
NCT07061535Extensive-stage Small Cell Lung Cancer (ES-SCLC), Extensive Stage Lung Small Cell Cancer, Extensive-Stage Small-Cell Lung Cancer, Extensive Disease Small Cell Lung Cancer
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
40
Changsha, Jinan, Hangzhou
2025-07-30
Not yet open
Benmelstobart, Anlotinib and Chemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer
NCT06931145Extensive-stage Small Cell Lung Cancer
Peking Union Medical College Hospital
Phase 4
50
Beijing
2025-04-15
Recruiting
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
NCT06726148Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Extensive-stage Small Cell Lung Cancer
Novartis Pharmaceuticals
Phase 1/2
280
Nanjing, Xian
2025-04-03
Recruiting
Clinical Study on Using TCR to Predict the Effect of Tislelizumab + Chemotherapy in the First-line Treatment of ES-SCLC
NCT07244016Extensive-stage Small-cell Lung Cancer
Henan Cancer Hospital
Observational
40
Zhengzhou
2025-02-20
Recruiting
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
NCT06712355Extensive-stage Small-cell Lung Cancer
BioNTech SE
Phase 3
621
Changchun, Baoding, Beijing, Bengbu, Fuzhou, Guangzhou, Hangzhou, Haโ€™erbin
2025-02-03
Recruiting
Maintenance Lurbinectedin in Combination With Serplulimab for Patients With ES-SCLC
NCT06497530Extensive-Stage Small Cell Lung Cancer
Guangzhou Institute of Respiratory Disease
Phase 2
30
Guangzhou
2024-12-01
Recruiting
Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)
NCT06598306Extensive Stage Small Cell Lung Cancer
Amgen
Phase 1
220
Changchun, Shanghai
2024-10-07
Active, closed
Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment
NCT06502977Extensive Stage Small Cell Lung Cancer
Amgen
Phase 2
32
Beijing, Chongqing, Fuzhou, Guangzhou, Jiangmen, Harbin, Wuhan, Tianjin
2024-08-27
Recruiting
Tislelizumab Combined With Chemotherapy and Thoracic Radiotherapy in ES-SCLC
NCT06536868Extensive-stage Small-cell Lung Cancer
Second Hospital of Shanxi Medical University
Phase 2
40
Jincheng, Jinzhong, Taiyuan
2024-08-01
Recruiting
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Extensive-stage Small Cell Lung Cancer
NCT06437509Extensive-stage Small-cell Lung Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
66
Shanghai
2024-06-13
Active, closed
Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab
NCT06211036Extensive-Stage Small-Cell Lung Cancer, Small-Cell Lung Cancer
Amgen
Phase 3
563
Beijing, Chongqing, Fuzhou, Quanzhou, Guangzhou, Guilin, Nanning, Cangzhou
2024-06-05
Recruiting
Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC
NCT06217757Lung Cancer, Extensive-stage Small-cell Lung Cancer
Sichuan University
Phase 1/2
45
Chengdu
2024-04-18
Not yet open
Safety and Efficacy of Adebrelimab Plus Irinotecan Liposome (II) With or Without Famitinib in ES-SCLC Pre-treated With Immunotherapy
NCT06332950Extensive-stage Small-cell Lung Cancer
Baohui Han
Phase 1/2
80
Shanghai
2024-04-01
Active, closed
Study of Low-Dose Radiotherapy Concurrent Chemotherapy With Serplulimab for Patients With ES-SCLC
NCT05765825Extensive-stage Small-cell Lung Cancer
Sichuan University
Phase 2
61
Chongqing, Shantou, Wuhan, Shenyang, Jinan, Shanghai, Chengdu, Guiyang
2023-03-07
Active, closed
A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab
NCT05142696Extensive Stage Small Cell Lung Cancer
Novartis Pharmaceuticals
Phase 1/2
55
Beijing, Shanghai
2022-07-13
Active, closed
Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
NCT05280470Extensive-stage Small-cell Lung Cancer
Daiichi Sankyo
Phase 2
187
Changchun, Changsha, Chengdu, Guangdong, Hangzhou, Linyi, Shanghai, Wuhan
2022-03-09
Active, closed
Low-dose Radiotherapy Combined With Durvalumab, Chemotherapy(EP) in the Treatment of ES-SCLC
NCT05092412Lung Cancer, Extensive-stage Small-cell Lung Cancer, Durvalumab
You Lu
Phase 2
30
Chongqing, Zhengzhou, Chengdu
2022-03-02
Rows per page Showing 1–21 of 21
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/condition/extensive-stage-small-cell-lung-cancer

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 21 of those studies listing the condition Extensive-Stage Small Cell Lung Cancer.

How many Extensive-Stage Small Cell Lung Cancer trials are recruiting in China?

12 of the 21 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 2 have not yet opened recruitment, 7 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Extensive-Stage Small Cell Lung Cancer), 21 studies
PhaseStudiesRecruitingShare
Phase 29542.9%
Phase 35323.8%
Phase 1/24219%
Observational114.8%
Phase 1114.8%
Phase 4104.8%

Most active sponsors

Lead sponsors with the most studies (Extensive-Stage Small Cell Lung Cancer)
Lead sponsorStudiesRecruiting
Amgen41
Sichuan Baili Pharmaceutical Co., Ltd.33
Novartis Pharmaceuticals21
Sichuan University21
Baohui Han10
BioNTech SE11
Bristol-Myers Squibb11
Daiichi Sankyo10
Guangzhou Institute of Respiratory Disease11
Henan Cancer Hospital11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.